| Outcome Measures: |
Primary: GMR for Cmax of empagliflozin, Geometric mean ratio (GMR) between combination and empagliflozin monotherapy for Cmax of empagliflozin, up to 10 days|GMR for AUC0-24h of empagliflozin, GMR between combination and empagliflozin in monotherapy for AUC0-24h of empagliflozin, up to 10 days|GMR for Cmax of dorzagliatin, GMR between combination and dorzagliatin monotherapy for Cmax of dorzagliatin, up to 15 days|GMR for AUC0-24h of dorzagliatin, GMR between combination and dorzagliatin in monotherapy for AUC0-24h of dorzagliatin, up to 15 days|Adverse events, Number of participants with AEs, up to 15 days|Abnormal vital signs, Number of participants with abnormal vital signs (blood pressure, pulse rate, respiratory rate and oral temperature), up to 15 days|Abnormal clinical laboratory findings, Number of participants with abnormal clinical laboratory findings, up to 15 days|12-lead ECG, Number of participants with abnormal ECG VR,, PR, QRS and QT, up to 15 days | Secondary: iCmax of glucose, The incremental peak plasma concentration of glucose post OGTT, up to 15 days|iAUC0-4h of glucose, The incremental area under the concentration-time curve of glucose in 4 hours post OGTT, up to 15 days|iCmax of insulin, The incremental peak plasma concentration of insulin post OGTT, up to 15 days|iAUC0-4h of insulin, The incremental area under the concentration-time curve of insulin in 4 hours post OGTT, up to 15 days|iCmax of C-peptide, The incremental peak plasma concentration of C-peptide post OGTT, up to 15 days|iAUC0-4h of C-peptide, The incremental area under the concentration-time curve of C-peptide in 4 hours post OGTT, up to 15 days
|
